Sporadic Inclusion Body Myositis Clinical Trial
Official title:
A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis
This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01925209 -
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05046821 -
Sporadic Inclusion Body Myositis Natural History Study
|
||
Completed |
NCT02573467 -
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
|
Phase 3 | |
Not yet recruiting |
NCT02735447 -
Evidence Generation for Improving Life of People With sIBM: The ENGAGE Study
|
N/A | |
Completed |
NCT02317094 -
Blood-flow Restricted Exercise in Inclusion Body Myositis
|
N/A | |
Completed |
NCT01519349 -
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
|
Phase 1 | |
Withdrawn |
NCT03710941 -
Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
|
Phase 2 | |
Completed |
NCT04421677 -
Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
|
Phase 1 |